HLS Therapeutics Dirección
Dirección controles de criterios 1/4
El CEO de HLS Therapeutics' es Craig Millian, nombrado en May 2023, tiene una permanencia de menos de un año. posee directamente un 0.031% de las acciones de la empresa, con un valor de CA$47.30K. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 2.1 años, respectivamente.
Información clave
Craig Millian
Chief Executive Officer (CEO)
n/a
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | less than a year |
| Participación del CEO | 0.03% |
| Permanencia media de la dirección | 3.4yrs |
| Promedio de permanencia en la Junta Directiva | 2.1yrs |
Actualizaciones recientes de la dirección
Recent updates
After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
Apr 14
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 06Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Nov 16Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Sep 13Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
May 05HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Apr 05HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
Mar 20HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of $0.05
Nov 30Downgrade: Here's How Analysts See HLS Therapeutics Inc. (TSE:HLS) Performing In The Near Term
Nov 11We Think HLS Therapeutics (TSE:HLS) Has A Fair Chunk Of Debt
Sep 14HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Aug 15HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Jul 14HLS Therapeutics (TSE:HLS) Has Announced A Dividend Of CA$0.05
Jun 23HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
Jun 08HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 25HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 10Time To Worry? Analysts Are Downgrading Their HLS Therapeutics Inc. (TSE:HLS) Outlook
Apr 30HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05
Apr 15HLS Therapeutics (TSE:HLS) Has Re-Affirmed Its Dividend Of CA$0.05
Mar 26HLS Therapeutics Inc. (TSE:HLS) Analysts Just Slashed This Year's Estimates
Mar 22HLS Therapeutics (TSE:HLS) Will Pay A Dividend Of CA$0.05
Nov 29HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05
Aug 10Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 30CEO
Craig Millian (55 yo)
less than a year
Permanencia
Mr. Craig Stuart Millian, MBA, is Chief Executive Officer and Director of HLS Therapeutics Inc. from May 1, 2023. He served as Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc. since Septemb...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Vice President of Scientific Affairs | 9.8yrs | US$319.52k | 0.16% $ 231.1k | |
| Senior VP of Legal | 5.9yrs | US$431.01k | 0.0016% $ 2.3k | |
| CEO & Director | less than a year | sin datos | 0.031% $ 46.5k | |
| Interim CFO & Non-Independent Director | less than a year | sin datos | 0.013% $ 18.6k | |
| Senior Vice President of Commercial | less than a year | sin datos | 0.0038% $ 5.6k | |
| VP & Corporate Controller | 6.3yrs | sin datos | sin datos |
3.4yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de HLS se considera experimentado (3.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | less than a year | sin datos | 0.031% $ 46.5k | |
| Interim CFO & Non-Independent Director | less than a year | sin datos | 0.013% $ 18.6k | |
| Independent Director | 5.1yrs | US$207.50k | sin datos | |
| Independent Chairman of the Board | 2.8yrs | US$210.00k | 0.30% $ 451.1k | |
| Independent Director | 6.1yrs | US$218.69k | sin datos | |
| Independent Director | 2.8yrs | US$206.43k | 0.0016% $ 2.3k | |
| Independent Director | 1.4yrs | US$18.05k | 0.0055% $ 8.2k | |
| Independent Director | less than a year | sin datos | sin datos |
2.1yrs
Permanencia media
55yo
Promedio de edad
Junta con experiencia: La junta directiva de HLS no se considera experimentada (2.1 años de permanencia promedio), lo que sugiere una nueva junta directiva.